# QuANTUM-First (NCT02668653)

> Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02668653
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Daiichi Sankyo
- Conditions: Acute Myeloid Leukemia; Leukemia
- Interventions: Chemotherapy; Quizartinib; Placebo
- Enrollment: 539
- Primary outcome: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

## Commentary we found

- Podcasts: 63
- YouTube: 57
- X threads: 20

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=quantum-first-nct02668653

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02668653", "email": "<work email>"}; the inbox owner confirms by the emailed link.